Penserra Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Penserra Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-605	Closed	-$28K	–	1369
2021 Q3	$28K	Buy	605 +5	+0.8%	+$224	﹤0.01%	1193
2021 Q2	$20K	Buy	600 +20	+3%	+$677	﹤0.01%	1143
2021 Q1	$23K	Buy	580 +20	+4%	+$1.19K	﹤0.01%	948
2020 Q4	$24K	Buy	+560	New	+$37.9K	﹤0.01%	826
2017 Q2	–	Sell	-1,941	Closed	-$15K	–	524
2017 Q1	$15K	Buy	1,941 +832	+75%	+$7.7K	﹤0.01%	406
2016 Q4	$16K	Buy	1,109 +478	+76%	+$7.15K	﹤0.01%	714
2016 Q3	$10K	Buy	631 +158	+33%	+$5.1K	﹤0.01%	796
2016 Q2	$15K	Sell	473 -2	-0.4%	-$63	﹤0.01%	503
2016 Q1	$12K	Buy	475 +158	+50%	+$5.35K	﹤0.01%	501
2015 Q4	$14K	Buy	+317	New	+$14.3K	﹤0.01%	457

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penserra Capital Management's ARCT Position: Q4 2021 in Review

Penserra Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2021, closing a stake of 605 shares — an estimated $28K sold.

Penserra Capital Management first reported a position in ARCT in Q4 2015 and held it in 10 quarters. The position peaked at $28K in Q3 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q4 2021.

Penserra Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 605 Arcturus Therapeutics shares in Q4 2021, an estimated $28K.
Penserra Capital Management first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 10 quarters.
Penserra Capital Management's Arcturus Therapeutics position peaked at $28K in Q3 2021.
139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.